Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice
Abstract Background Pregnant women are at increased risk of thrombotic adverse events. Plasma derived immune globulin (IG) products, which are used in pregnancy for various indications, may contain procoagulant impurity activated coagulation factor XI (FXIa). Procoagulant IG products have been assoc...
Main Authors: | Yanqun Xu, Yideng Liang, Leonid Parunov, Daryl Despres, Michael Eckhaus, Dorothy Scott, Mikhail Ovanesov, Evi B. Struble |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | Thrombosis Journal |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12959-020-00245-8 |
Similar Items
-
Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays
by: Yideng Liang, et al.
Published: (2021-01-01) -
Isradipine decreases arterial thrombogenicity in rabbits
by: P Fitscha, et al.
Published: (2001-01-01) -
Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation
by: Gil Bu Kang, et al.
Published: (2023-11-01) -
Contact Pathway Function During Human Whole Blood Clotting on Procoagulant Surfaces
by: Shu Zhu, et al.
Published: (2018-07-01) -
Polymer-Drug Anti-Thrombogenic and Hemocompatible Coatings as Surface Modifications
by: Barbara Zawidlak-Węgrzyńska, et al.
Published: (2024-03-01)